Sagar Sardesai
Overview
Explore the profile of Sagar Sardesai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
409
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coombes R, Howell S, Lord S, Kenny L, Mansi J, Mitri Z, et al.
Nat Commun
. 2025 Mar;
16(1):2242.
PMID: 40050276
No abstract available.
2.
Azam S, Asad S, Chitnis S, Collier K, Kensler K, Sudheendra P, et al.
J Nutr
. 2024 Sep;
154(11):3437-3445.
PMID: 39277115
Background: The empirical dietary inflammation pattern score (EDIP), which measures the ability of the diet to regulate chronic inflammation, is associated with both higher adiposity and breast cancer (BC) risk....
3.
Sukumar J, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, et al.
Cancer Med
. 2024 Jun;
13(12):e7317.
PMID: 38895891
Background: The optimal adjuvant endocrine therapy (ET) in hormone receptor positive (HR+) and human epidermal growth factor receptor 2 positive (HER2+) premenopausal breast cancer (BC) remains unclear. Moreover, the benefit...
4.
Minta A, Rose L, Park C, Ramaswamy B, Stover D, Gatti-Mays M, et al.
Support Care Cancer
. 2023 Nov;
31(12):717.
PMID: 37991653
Purpose: Dermatologic adverse events commonly result in the interruption of oncologic treatment, and targeted therapies are the most frequently interrupted class of anticancer agents. Alopecia is a common cutaneous adverse...
5.
Johnson K, Grimm M, Sukumar J, Schnell P, Park K, Stover D, et al.
Breast
. 2023 Oct;
72:103591.
PMID: 37871527
Inflammatory breast cancer (IBC) poses an ongoing challenge as rates of disease recurrence and mortality remain high compared to stage-matched controls. However, frontline therapy has evolved through the years, including...
6.
Coombes R, Howell S, Lord S, Kenny L, Mansi J, Mitri Z, et al.
Nat Commun
. 2023 Aug;
14(1):4741.
PMID: 37550302
No abstract available.
7.
Coombes R, Howell S, Lord S, Kenny L, Mansi J, Mitri Z, et al.
Nat Commun
. 2023 Jul;
14(1):4444.
PMID: 37488191
Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we...
8.
Johnson K, Goldstein D, Tharakan J, Quiroga D, Kassem M, Grimm M, et al.
Oncol Ther
. 2023 Jun;
11(3):361-374.
PMID: 37354381
Introduction: The immunomodulatory impact of corticosteroids and concurrent chemotherapy is poorly understood within triple-negative breast cancer (TNBC). On a biochemical level, steroids have been linked to the signaling of chemotherapy-resistant...
9.
Asad S, Damicis A, Heng Y, Kananen K, Collier K, Adams E, et al.
Breast Cancer Res
. 2022 Nov;
24(1):78.
PMID: 36376974
Background: Breast tumor immune infiltration is clearly associated with improved treatment response and outcomes in breast cancer. However, modifiable patient factors associated with breast cancer immune infiltrates are poorly understood....
10.
Ballinger T, Djuric Z, Sardesai S, Hovey K, Andrews C, Brasky T, et al.
Nutr Cancer
. 2022 Aug;
75(1):265-275.
PMID: 35968582
Proton pump inhibitors (PPIs) have off-target activity on fatty acid synthase (FASN), a critical enzyme in energy balance and cancer growth. We evaluated risk of common obesity-related cancers: breast, colorectal...